The EVAN study compared adjuvant erlotinib therapy with standard vinorelbine and cisplatin administered for 2 years, in patients with EGFR-mutant stage IIIA NSCLC who had undergone resection. Here, EGFR is linked to non-small cell lung carcinoma.